Dow Jones
38.024,89 +121,60 (+0,32%) Nasdaq
15.714,04 +108,56 (+0,70%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0708 -0,0010 (-0,10%) Bitcoin EUR
55.125,90 +1.923,88 (+3,62%) CMC Crypto 200
1.276,39 +5,65 (+0,44%)
Arbutus Biopharma Corporation (ABUS)
| Chiusura precedente | 2,6900 |
| Aperto | 2,6400 |
| Denaro | 2,6900 x 200 |
| Lettera | 2,7100 x 400 |
| Min-Max giorno | 2,6300 - 2,7300 |
| Intervallo di 52 settimane | 1,6900 - 3,2900 |
| Volume | |
| Media Volume | 1.401.554 |
| Capitalizzazione | 486,473M |
| Beta (5 anni mensile) | 2,09 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4400 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,40 |
GlobeNewswireArbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that clinical data from the Company’s lead HBV focused asset, imdusiran (AB-729), an RNAi therapeutic, and preclinical data from its oral PD-L1 inhibitor program, will
- GlobeNewswire
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor Discontinuing all coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161 Extending cash runway through Q3 2025 WARMINSTER, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that tar
- GlobeNewswire
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference: Formal Presentation on September 12, 202
